Prothena Corp Public LTD Co (PRTA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $8.36
- As of
Kresmion compiles this page from PRTA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
PROTHENA CORP PUBLIC LTD CO (PRTA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-02.
See the full PRTA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for PRTA on one page. Preview it with sample data, then open it live with a free account.
Preview the PRTA dossierActive signals for PRTA
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 9.7%, EPS $-0.36 vs $-0.3988 estimate
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +1246% to PRTA (2026Q1)
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +80% to PRTA (2026Q1)
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 29.8% - EPS $-0.4 vs $-0.57 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 28.9% - EPS $-1.73 vs $-1.3426 estimate
FREE, NO ACCOUNT
Every signal on PRTA, as it fires
You are seeing 5 of 7 signals recorded on PRTA since 2026-05-17.
The five above landed across 4 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, PRTA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
PRTA against its peers
PRTA's operating margin of -2216.4% ranks in the 23rd percentile of 10 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | PRTA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.7M USD | 7.3M USD | 54 | 13 |
| Operating margin | -2216.4% | -376.9% | 23 | 10 |
| Net margin | -2520.6% | -310.8% | 23 | 10 |
| Return on equity | -87.0% | -50.5% | 28 | 19 |
| 1 year | -19.2% | -22.2% | 50 | 14 |
Peers (20): YDES, ENTX, TECX, CAPR, DMAC, AUTL, RZLT, ZURA, EPRX, SPRY, ASMB, OVID, MYGN, ARVN, KYTX, NGNE, MPLT, OCS, ALT, EDIT. Left out: PRTC (period gap), AGMB (no annual filing), EIKN (no annual filing), TRXB (no annual filing), DRUG (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (PRTA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow PRTA on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to PRTA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.